A phase II study shows that DNA mismatch repair deficiency can render tumors highly sensitive to the PD-1 inhibitor pembrolizumab. Patients with a range of solid tumors, including colorectal and endometrial cancers, with the deficiency responded well and durably to immune checkpoint blockade, with minimal toxicity.
from Cancer via ola Kala on Inoreader http://ift.tt/2aqOYNC
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου